ERBB2 and androgen insensitivity syndrome: In contrast, adenocarcinoma in situ (AIS) and adenocarcinoma showed strong expression of RTKs (EGFR, HER2 or c-Met) on the cell membrane in 41 (77.4%) of the 53 cases.